Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization
Open Access
- 1 March 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Journal of Pain Research
- Vol. ume 13, 537-545
- https://doi.org/10.2147/jpr.s230680
Abstract
Background: Studies have shown that interferon-beta (IFN-β) treatment is associated with headaches in patients with multiple sclerosis (MS). Headaches can affect quality of life and overall function of patients with MS. We examined the frequency, relationships, patterns, and characteristics of headaches in response to IFN-β in patients with relapsing-remitting multiple sclerosis (RRMS). Patients and Methods: This study was a prospective, longitudinal analysis with 1-year follow-up. The study comprised 796 patients with RRMS treated with IFN-β (mean age 30.84± 8.98 years) at 5 tertiary referral center outpatient clinics in Egypt between January 2015 and December 2017. Headaches were diagnosed according to the International Classification of Headache Disorders ICHD-3 (beta version), and data were collected through an interviewer-administered Arabic-language-validated questionnaire with an addendum specifically designed to investigate the temporal relationship between commencement of interferon treatment, and headache onset and characteristics. Results: Two hundred seventy-six patients had pre-existing headaches, and 356 experienced de novo headaches. Of 122 patients who experienced headaches before IFN-β treatment, 55 reported headaches that worsened following onset of IFN-β treatment. In patients with post-IFN-β headaches, 329 had headaches that persisted for > 3 months, 51 had chronic headaches, and 278 had episodic headaches, and 216 of these patients required preventive therapies. Univariate analysis showed a > 6- and an approximately 5-fold increased risk of headache among those treated with intramuscular (IM) INF-β-1a (OR 6.51; 95% CI: 3.73– 10.01; P-value < 0.0001) and 44 μg of SC INF-β-1a (OR 5.44; 95% CI: 3.15– 9.37; P-value < 0.0001), respectively, compared with that in patients who received 22 μg of SC INF-β-1a. Conclusion: Interferon-β therapy aggravated pre-existing headaches and caused primary headaches in patients with MS. Headache risk was greater following treatment with IM INF-β-1a and 44 μg SC INF-β-1a.Keywords
This publication has 43 references indexed in Scilit:
- Reference programme: Diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd Edition, 2012The Journal of Headache and Pain, 2012
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Cross-sectional study assessing long-term safety of interferon-β-1b for relapsing-remitting MSNeurology, 2010
- Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week resultsMultiple Sclerosis Journal, 2008
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialThe Lancet Neurology, 2008
- Migraines Linked to Interferon-β Treatment of Multiple SclerosisAmerican Journal of Physical Medicine & Rehabilitation, 2005
- Prevalence of Primary Headaches in People with Multiple SclerosisCephalalgia, 2004
- Tension-type headaches: what they are and how to treat themPrimary Care: Clinics in Office Practice, 2004
- Randomized, comparative study of interferon β-1a treatment regimens in MSNeurology, 2002
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996